Altogether, this discovery, along with the low FARSA levels in MCL patients (Figure 1C) as well as the negative correlation between FARSA and CCND1 (Figure 1D), suggests that FARSA may serve as a tumor suppressor in MCL, and low FARSA levels may confer chemoresistant properties to MCL cells. Here, FARSA is linked to neoplasm.